Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Stock Slides 10 Percent on Q2 Revenue Decline

NEW YORK (GenomeWeb News) - Shares in CombiMatrix were down 10 percent, or $.14, at $1.22 in mid-afternoon trading today after the company reported a decline in revenues for the second quarter.
 
As GenomeWeb News reported today, total revenues declined 3.5 percent to $1.79 million, though revenues from product sales more than doubled.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.